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Objective: To assess the expression of calpains and calpain-induced aggrecan fragmentation in early and
advanced stages of degeneration of human intervertebral discs (IVDs).
Design: Disc tissue samples of 55 patients (mean age, 51.2  22.3 years) who underwent intervertebral
fusion were divided into groups with early and advanced degeneration based on the Thompson magnetic
resonance imaging (MRI) scale. In advanced degeneration group, ﬁve patients (mean age,
35.5  11.4 years) of lumbar disc herniation (LDH) were included. Protein levels of m- and m-calpains and
their inhibitor calpastatin were assayed, and immunohistochemical techniques were used to localize and
quantify the production of the enzymes. To investigate calpain activity, we assayed puriﬁed aggrecan
fragmentation in disc tissue by Western blotting and immunohistochemistry with VPGVA antibody,
which recognizes the m-calpain generated neo-epitope GVA.
Results: Discs at early stages of degeneration expressed low levels of m- and m-calpains and calpastatin,
and few cells expressed degenerative enzymes. At more advanced stages of degeneration, the expression
and number of cells immunopositive for m-calpain, m-calpain and calpastatin were signiﬁcantly higher.
Further ﬁnding showed that anti-GVA-reactive aggrecan fragments were signiﬁcantly higher in discs at
advanced compared with early stages of degeneration. Herniated disc samples showed stronger
expression and more cells immunopositive for calpains, calpastatin and GVA in the nucleus pulposus
than in the annulus ﬁbrous.
Conclusions: The expression of calpains, together with m-calpain-induced degradation products of
extracellular matrix, was correlated with the degree of disc degeneration in human IVD tissue. These
ﬁndings suggest that calpains may be involved in IVD degeneration via proteoglycan (PG) cleavage.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The causes of low back pain are multifactorial, although, in
about 40% of patients, it involves degeneration of the intervertebral
discs (IVDs)1. During degeneration, the extracellular matrix (ECM)
in which the major structural components of IVD can become
highly disorganized and denatured2,3.
Since inﬂammatory cytokines are present in degenerated disc
tissue4, inﬂammation is now regarded as a possible initiator of IVD
degeneration5e7. In vitro, inﬂammatory cytokines have been shownKei Miyamoto, Department of
University Graduate School of
an. Tel: 81-(0)-58-230-6333;
o).
s Research Society International. Pto cause a loss of PGs in the ECM of human disc cells7,8. While
aggrecan degeneration in the IVD is a marker of the catabolism of
matrix components, several families of proteinases including
aggrecanases7,9,10 and matrix metalloporoteinases (MMPs)11e13
have been found in degraded human IVD. Moreover, speciﬁc
products of aggrecan cleavage by aggrecanases9,12 and MMPs12
have also been detected.
Calpains are a family of calcium-dependent cytosolic cysteine
proteinases that catalyze the limited proteolysis of proteins
involved in cytoskeletal remodeling and signal transduction,
moreover, it has also been implicated in other physiological,
structural, mechanical, and molecular changes resulting in a loss of
demarcation between the annulus ﬁbrous (AF) and nucleus pul-
posus (NP). In degenerated IVD, the loss of ECM components
exceeds new synthesis, whereas, in normal IVD, the turnover and
synthesis of ECM molecules are at equilibrium9,14,15. Disc compo-
sition changes with age, leading to a state of disc degenerationublished by Elsevier Ltd. All rights reserved.
Table I
Data for patient samples
Early degeneration Advanced degeneration
No 5 45
Age 12.3  3.5 y.o. (12e16) 63.2  15.1 y.o. (43e85)
Gender Male: 3, Female: 2 Male: 21, Female: 24
Diagnosis Idiopathic scoliosis: 5 Spondylolisthesis: 30
DDD: 15
Donor site (spinal level)
of disc samples
Lumbar 1/2 (n ¼ 1) Lumbar 1/2 (n ¼ 2)
Lumbar 2/3 (n ¼ 2) Lumbar 2/3 (n ¼ 8)
Lumbar 3/4 (n ¼ 2) Lumbar 3/4 (n ¼ 11)
Lumbar 4/5 (n ¼ 14)
Lumbar 5/S (n ¼ 10)
Operation ALIF:5 ALIF:5
TLIF or PLIF:40
Supplement Herniated disc samples
5 (Male: 3, Female: 2)
35.5  11.4 y.o. (25e41)
S: Sacral; DDD: Disc degeneration disease; TLIF: Transforaminal interbody fusion;
PLIF: Posterior lumbar interbody fusion.
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factors. Changes in collagen type and decreased proteoglycan (PG)
content result in loss of tissue integrity, decreased hydration, and
inability to withstand load14e17, decreasing the viscoelastic prop-
erties of the disc matrix18. Finally, these degenerative changes
contribute to degenerative disc disease, spondylolisthesis, and
pathological processes, such as cell cycle regulation, apoptosis,
muscular dystrophies, cataractogenesis, and Alzheimer’s and Par-
kinson’s diseases19,20. The calpains constitute a large family of
distinct isozymes that differ in structure and distribution, with the
two best characterized members of this family being ubiquitous-
m-calpain (calpain-1) and m-calpain (calpain-2)21,22. Further, cal-
pastatin, a speciﬁc endogenous protein inhibitor, has been shown
to modulate calpain activity in vivo23. Calpains, which are abun-
dantly present in human articular cartilage, are involved in the
proteolysis of cartilage24,25 and can proteolyze aggrecan under
neutral conditions9,26. The sites of aggrecan cleavage by m-calpain
were found to be at VPGVA709-A710VPVE27. Although the localiza-
tion of aggrecan fragments proteolyzed by calpains in human
articular cartilage has suggested a possible role for calpain in the
degradation of cartilage25, these fragments have not been precisely
localized in human IVD. Furthermore, little is known about the
association between calpains and IVD degeneration.
Although articular cartilage and IVD have several biochemical
properties in common, little is known about the potential function
of calpains in IVD degeneration. Direct injection of calpain into
rabbit IVDs resulted in histological degeneration, disc height loss,
and a signiﬁcant decrease in uronic acid content28. Although
neither endogenous calpains in IVD tissue nor calpain-induced
degradation products of ECM were demonstrated, the structural
changes in rabbit IVD tissue observed after injection of calpains
suggests that these enzymes may play a role in IVD degeneration.
While many studies have examined the cleavage of aggrecan at
aggrecanase sites in articular cartilage, little is known about their
contribution to aggrecan degradation in IVDs10,29.
Given those backgrounds, we hypothesized that if calpain is
involved in the degeneration process in human IVDs, calpain, its
inhibitor, and calpain cleaved fragments of aggrecan would be
present in IVDs. In addition, an increase in cleaved aggrecan
products in IVDs at advanced stages of degenerationwould suggest
a positive role for calpain in the IVD degeneration process. We
therefore assessed the levels of expression and the localization of
calpains and its inhibitor in human IVDs, at early and advanced
stages of degeneration. In addition, in order to further assess the
function of calpains in the metabolism of aggrecan in human IVDs,
we measured the amounts of GAG-bearing aggrecan products




IVD samples were obtained from patients who underwent
spinal fusion operations from April 2007 to May 2009 in our
hospital. Informed consent was obtained from patients or their
relatives to obtain human tissue samples. The gross morphology of
each disc was graded using the Thompson grading scheme (grade I,
two patients; grade II, three patients; grade IV, 35 patients; grade V,
10 patients) by MRI T2 imaging30. The samples were divided into
two groups, those with early degeneration (grades I and II, ﬁve
patients) and those with advanced degeneration (grades IV and V,
45 patients) (Table I). Samples were also obtained from the lumbar
herniated discs of ﬁve patients (each grade III) with recurrent
intervertebral disc hernia who underwent interbody fusion.Extracts of NP samples were taken from the center parts and AF
samples from the outer parts near the ligament of the IVD. In
harvesting NP and AF tissues from degenerated discs, we estimated
their positions from the morphology of normal non-degenerated
discs. This procedure was performed by a spine surgeon of
10 years experience. Archived blocks of full thickness IVDwedges of
120 degrees from 12 samples (seven from males; three with early
and two with advanced degeneration and two with LDH; and ﬁve
from females, two each with early and advanced degeneration and
one with LDH), each incorporating AF and NP, were ﬁxed in 10%
neutral buffed formalin and embedded in parafﬁn. Sections were
taken for staining with hematoxylin and eosin.
Chemicals
Rabbit polyclonal antibody against m-calpain (AB1625, Chem-
icon; Temecula, CA, USA), mouse monoclonal antibody against
m-calpain (MAB3082, Chemicon) and mouse monoclonal antibody
against calpastatin (sc-20779, Santa Cruz Biotechnology; Santa
Cruz, CA, USA), and mouse monoclonal antibody against b-actin
(sc-10731, Santa Cruz) were obtained from their manufacturers.
Proteinase free chondroitinase ABC (100332) and keratanases I and
II (100810 and 100812) were obtained from Seikagaku Corporation
(Tokyo, Japan). Western Lighting Chemiluminescence Reagent Plus
was obtained from Perkin Elmer LAS (Boston, MA, USA). Quanti-
tative changes in luminescence were estimated by LAS-1000 UV
mini and Multi Gauge Ver.3.0 (Fujiﬁlm, Japan). All other reagents
were obtained from standard commercial sources.
Western blot analysis for calpains and calpastatin in IVD tissues
Tissue samples of all patients (AF: 40 mg, NP: 40 mg) (Early: ﬁve
patients, Advanced: 45patients, LDH:ﬁve patients)were suspended
in lysis buffer (300 ml) (1% Nonidet P-40, 0.5% sodium cholate,1 mM
EDTA,1mM EGTA,150mMNaCl, 20mMHEPES, 3mMMgCl2, 1 mM
phenylmethylsufonyl ﬂuoride, 20 mg/ml leupeptin, 20 mM b-glyc-
erophosphate, 1 mM NaF, and 1 mM sodium orthovandate, pH 7.4)
and sonicated at 20 kHz three times for 20 s each, with 10 min icing
between sonications, using an Astrason XL sonicator (Misonix, New
York, USA). Following centrifugation, the protein concentrations of
the supernatants were determined using the Bradford protein
assay reagent (Bio-Rad). Samples were separated on SDS–poly-
aclylamidegel electrophoresis (SDS–PAGE) (5e20% gradient gels)
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Millipore). After blockingwith 5% fat freemilk, themembraneswere
washed, incubated with primary antibody, washed again, and
incubated with secondary antibody. The level of expression was
estimated quantitatively by densitometric analysis of the Western
blots. The optical density of each target protein was normalized to
that of the 45 kDa b-actin band. Each blot shown is representative of
three independent experiments.We conductedWestern blotting for
all 55 patients both AF and NP on each for calpains and calpastatin.
Further, immunoblotting of all samples were repeated three times.
Data with coefﬁcient variation (CV) of less than 10% of Western
blotting was regarded as reproducible.
Immunohistochemical assays of calpains and calpastatin in IVD
tissues
Immunohistochemistry was performed on samples obtained
from anterior lumbar interbody fusion (ALIF) operations, which
were performed on 12 patients: ﬁve with idiopathic scoliosis,
four with degenerative spondylolisthesis and disc degeneration,
and three with disc herniation. Parafﬁn sections (4 mm) were
stained, deparafﬁnized with xylene and rehydrated through
a series of alcohols to phosphate buffed saline (PBS). Endogenous
peroxidase activity was blocked by sequential incubation with
0.3% hydrogen peroxidase and 3% bovine serum albumin, each in
PBS. Samples were immunoperoxidase stained using the DAKO
EnVion System (DAKO Corp., CA, USA), by incubation with
primary antibody for 90 min at room temperature. The primary
antibodies used were rabbit anti-m-calpain polyclonal antibody
(1:100); mouse anti-m-calpain monoclonal antibody (1:100); and
mouse anti-calpastatin monoclonal antibody (1:100). The
samples were washed with PBS and incubated overnight at 4C
with labeled polymer horseradish peroxidase (HRP) anti-Rabbit/
Mouse. Following thorough washing, the samples were incu-
bated with DAB (3,30-diaminobenzidine) for 10 min. The samples
were washed, dehydrated, and mounted in Pertex. Figure plates
were prepared using Adobe Photoshop (Adobe System, Inc.,
Mountain View, CA). For analysis, each disc was morphologically
separated into three areas, with the NP being at the center of the
IVD, the inner-AF within 5 mm of the edge of AF, and the outer-
AF at up to 5 mm from the edge of the ligament. Within each
area, 200 cells were counted and the number of immunopositive
cells was determined6. Numbers of immunopositive cells were
counted in three different areas of each sample and CV among
the three values obtained. The results showed that the CVs were
less than 20% (11% in the early NP, 17% in the advanced NP, 15% in
the LDH-NP, 17% in the early IAF, 18% in the advanced IAF, and
19% in the LDH-IAF), consequently showing that our method for
counting cells provides relatively reproducible number of
immunopositive cells in each condition. Data were plotted as the
mean  S.E.M., with 95% conﬁdence intervals. The proportions of
immunopositive cells by grade were compared using the
ManneWhitney U test.
Aggrecan extraction from discs
For all patients samples, PGs within IVD samples were extracted
at 4C for 48 h with 4 M guanidine hydrochloride (GuHCl) in
100 mM sodium acetate, pH 6.8, 10 mM EDTA, 100 mM
6-aminohexanoic acid, 10 mM benzamidine HCl, 10 mM N-etyl-
maleimide and 1 mM phenylmethyl sulphonyl ﬂuoride31. After
dialysis against 50 mM sodium acetate, pH 6.0, plus protease
inhibitors (10 mM EDTA, 100 mM 6-aminohexanoic acid, 5 mM
benzamidine HCL, 1 mM PMSF), each sample was adjusted with
solid GuHCl to a GuHCl concentration of 0.5 M and its density wasadjusted to 1.6 g/ml by adding solid cesium chloride. The samples
were centrifuged at 71,500g for 72 h at 10C. The resulting
gradients were fractionated into four equal parts to yield fractions
A1eA4 from the bottom of the tubes. Then A1 fractionwas adjusted
to dissociative conditions by addition of solid GuHCl to 4 M and the
density was adjusted to 1.47 g/ml by addition of solid cesium
chloride and centrifuged at 71,500g for 48 h at 10C. The resulting
gradients were fractionated into four equal parts to yield fractions
A1D1eA1D4 from the bottom of the tubes. The samples were
dialyzed at 4C against 0.05 M sodium acetate pH 6.8 with protease
inhibitors, and ﬁnally dialyzed against distilled water. The samples
were freeze-dried and stored at 80C.
Detection of aggrecan lytic activity
In a preliminary investigation, we tested A1D1, A1D2, A1D3
and A1D4 from human disc samples against anti-GVA antibody,
showing that the intensity of the bands was consistent
A1D1 > A1D2 > A1D3 > A1D4 (data not shown). We therefore
tested the A1D1 fraction in this study. We also examined these
fractions after guanidinium dialysis. The freeze-dried A1D1
samples were dissolved in 50 mM sodium acetate, 50 mM Tris,
10 mM EDTA, pH 7.6, and sulphated gylcosaminoglycans were
assayed by the 1,9-dimethylmethylene blue assay32. For degly-
cosylation, samples in solution were incubated with protein free
chondroitinase ABC (0.1 U/100 mg GAG) for 2 h at 37C, adjusted
to 1 mM PMSF and 10 mM N-etylmaleimide and incubated with
keratanases I (0.1 U/100 mg GAG) and II (0.01 U/100 mg GAG) for
1 h33. The deglycosylated PGs were separated on 4e12%
SDSePAGE gels (Super Sep ace, Wako, Japan) and transferred to
membranes using the wet transfer method. The membranes
were incubated with VPGVA antibody (1:3000), which recog-
nizes the aggrecan cleavaged by m-calpain followed by incuba-
tion with anti-rabbit-IgG (1:3000, Dako, P0448). Western
Lighting Plus-ECL (Perkin Elmer, Waltham, USA) was used.
VPGVA antibody was used in our in situ study of articular carti-
lage25. Western blotting was conducted for all 55 patients both
AF and NP for GVA. Further, immunoblotting of all samples were
repeated three times.
Statistical analysis
Student’s t tests were used for comparisons between groups of
samples from patients with early and advanced stages of disc
degeneration. ManneWhitney tests were used for between group
comparisons of the proportion of cells expressing each protein
within the NP, inner-AF, and outer-AF areas, and the Wilcoxon
paired sample test was used to compare the proportions of
immunopositive cells in different areas of the discs (i.e., NP vs
inner-AF, NP vs outer-AF, and inner-AF vs outer-AF). This analysis
was performed using all disc sections, regardless of level degen-
eration. Further, post-hoc TukeyeKramer test was used to compare
the intensity of protein expression for Western blots of GVA. All
statistical analyses were performed using Stat View 5.0 (SAS
Institute, Cary, NC).
Results
Expression of calpains and calpastatin in human IVDs
M-calpain, m-calpain and calpastatin were expressed in the AF
and NP areas of both early and advanced degenerated human IVDs.
All the samples from IVD tissue demonstrated a clear positive band
at 80 kDa, corresponding to the large subunit of m-calpain34. In
addition, bands at 80 kDa, corresponding to m-calpain, and at
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[Fig. 1(A)] The expression of all three proteins was higher in
samples from advanced degenerated disc than in samples from
early degenerated discs. [Fig. 1(B)] There were no differences,
however, between the NP and AF areas for early and advancedFig. 1. A: Western blotting with each antibody. Left panel: The molecular masses of m
samples from NP were sonicated, with 20 mg protein loaded per lane. Right panel: Molecu
20 mg GAG from NP after treatment with the deglycosylation enzymes keratanases I and
a negative control. A band corresponding to GVA was observed in lane A (black arrow). B: Re
IVD tissues at early and advanced stages of degeneration. Western blot analyses of protei
ﬁndings in all 55 patients (ﬁve early, 50 advanced include ﬁve LDH). 20 mg protein were load
degenerated are shown. One bracket (AeN) represents samples from the one patient. Patien
m-calpain, and calpastatin detected single bands of molecular mass 80 kDa, 80 kDa and 115degenerated discs. Quantitative analysis of Western blotting
results showed that the expression of all three proteins, m-calpain,
m-calpain and calpastatin, was signiﬁcantly higher in advanced
than in early degenerated disc samples within both the AF and NP
(P < 0.001) (Table II).-calpain, m-calpain, calpastatin (80 kDa, 80 kDa, 115 kDa, respectively). All protein
lar masses positive for GVA (140 kDa). Lane A shows blotting of the A1D1 fraction of
II and chondroitinase ABC. Lane B shows blotting of the deglycosylation enzymes as
presentative expression of m-calpain, m-calpain and calpastatin proteins in human
ns from the AF and NP areas of human IVD tissue. Results shown are representative of
ed onto each lane. In present ﬁgure, Western blots from three early and three advanced
t number on each bracket is common to each ﬁgure in Fig. 1B. Antibodies to m-calpain,
kDa, respectively.
Table II
Densitometric analysis of Western blotting for m-calpain, m-calpain and calpastatin/
b-actin proteins in human IVD tissues at early and advanced stages of degeneration.
(Mean difference shows difference between Early and Advanced group (95%CI))





m-calpain AF 1.0  0.1 3.2  0.7 2.17 (1.57, 2.76) <0.001
NP 0.9  0.1 3.0  0.7 2.05 (1.38, 2.72) <0.001
m-calpain AF 1.0  0.2 3.1  0.8 2.09 (1.40, 2.79) <0.001
NP 1.0  0.1 3.0  0.7 1.98 (1.37, 2.59) <0.001
Calpastatin AF 1.0  0.1 2.1  0.2 1.06 (0.88, 1.24) <0.001
NP 1.1  0.1 2.4  0.2 1.24 (1.06, 1.42) <0.001
The P values were calculated with Student’s t test.
n: number of patients.
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the proportion of immunopositive cells for each
Using antibodies against m-calpain, we observed nuclear and
cytoplasmic staining (arrows) of disc cells in the AF and NP of both
early and advanced degenerated samples, with the percent positive
cells being higher in advanced than in early degenerated samples.
The location and ratio of immunopositive cells were similar in LDH
as in advanced degenerated samples. Immunopositive tendencies
were also detected for both m-calpain and calpastatin (Fig. 2). Low
proportions of cells in the NP and inner-AF areas of early degen-
erated samples were positive for m-calpain, m-calpain and calpas-
tatin. In NP areas of advanced degenerated samples, however,
72  10% [mean  standard deviation (SD)] of the cells stained
positive for m-calpain, 63  16% for m-calpain, and 52  12% for
calpastatin. In the inner-AF areas of advanced degenerated samples,
58  11% of the cells stained positive for m-calpain, 49  12% for
m-calpain, and 4310% for calpastatin. In NP areas of herniated disc
samples, 73  7.3% of the cells stained positive for m-calpain,
52 10% for m-calpain, and 58 9.0% for calpastatin. These ﬁndings
indicate that the proportions of cells in the NP and inner-AF of
advanced degenerated and in the NP of LDH samples positive for
the calpains and calpastatin increased signiﬁcantly as degeneration
or herniation became more severe (P < 0.05) (Table IV). On the
other hand, there were no signiﬁcant differences in the proportion
of cells positive for m-calpain, m-calpain and calpastatin in the
outer-AF areas. However, there were no signiﬁcant differences in
the proportion of AF cells positive for calpains and calpastatin
between LDH tissue and early degenerated tissue (Table IV). All IgG
controls were negative.Aggrecanolytic activity of m-calpain in IVD tissue
M-calpain proteinase-generated fragments were detected using
GVA antibody. Western blot analyses using anti-VPGVA antibody
showed that a speciﬁc 140 kDa band was present in each sample
from early and advanced degenerated tissue sample and in the AF
and NP areas of each. (Fig. 3) Level of GVA fragments was signiﬁ-
cantly higher in tissues from patient with advanced thanwith early
degeneration (P < 0.001). Further, staining was signiﬁcantly
stronger in severe degeneration grade V samples than in mild
degeneration grade IV samples (P < 0.05). Level of GVA fragments
was similar in the NP and AF areas of advanced degeneration
samples, but was signiﬁcantly higher in the NP than in the AF areas
of herniated discs (P ¼ 0.001) (Table III). In immunohistochemistry,
using polyclonal antibody against GVA, we detected nuclear and
cytoplasmic immunopositivity (arrows) in both the AF and NP of
early and advanced degenerated samples. Similar ﬁndings were
observed for the calpains and calpastatin (Fig. 4).Proportion of cells immunopositive for GVA
In the NP and inner-AF areas of advanced degenerated samples,
74  13% and 63  13% of the cells, respectively, stained positive for
GVA. In the NP and inner-AF areas of herniated disc samples,
79  15% and 54 14% of the cells, respectively, stained positive for
GVA. These ﬁndings indicate that the proportions of cells in these
two areas immunopositive for GVA increased signiﬁcantly as
degeneration or herniation became more severe (P < 0.05).
Calculations of the coefﬁcients of variation among the results from




We have shown here for the ﬁrst time that both the NP and AF
areas of human IVDs contain calpains and calpastatin. In addition,
these areas contained the GVA fragment, generated by m-calpain
proteolysis. Interestingly, the expression of both the calpains and
GVA fragments was signiﬁcantly higher in IVDs at advanced than at
early stages of degeneration. Those ﬁndings suggest that the cal-
pains may play a role in IVD degeneration.
Abundance of calpain in degenerated discs
MMPs and a disintegrin and metalloprotease with thrombo-
spondin motifs (ADAMTS), enzymes known to initiate articular
cartilage degradation, have been observed in both degenerated and
herniated IVDs10,11,35,36. The calpains may be other candidate
proteases involved in the breakdown of articular cartilage in
arthritic diseases25e27,37,38.While the enzyme ADAMTS4 is involved
in the cleavage of aggrecan during human IVD degeneration9, cal-
pain also may be important for aggrecan cleavage by proteinase.
However, the involvement of calpains in ECM breakdown is still
unclear. Thus, our ﬁnding, of high expression of the calpains and
GVA fragments in degenerated IVD tissues, may shed light on the
potential function of calpain in the initiation and progression of IVD
degeneration.
GVA expression in normal human IVDs
In bovine auricular cartilage, the aggrecan product equivalent to
G1-G2-GVA, which is generated by calpains, was detected using an
equivalent monoclonal antibody, SK-2826,37. This aggrecan product
was not found in fetuses, but only in mature samples37. In using
human IVD tissues, however, we found that G1-G2-GVA was
present in IVDs from younger people and in degenerated IVDs.
Moreover, the GVA product was detected in samples from both
newborns and children39. Suggesting that, in addition to its
involvement in IVD degeneration, calpain is also involved in the
normal aggrecan turnover process in human tissues. We found that
the levels of expression of calpains, calpastatin and GVA were
signiﬁcantly higher in the NP and inner-AF than in the outer-AF.
Although, the aggrecan content is lower in the outer-AF than in the
NP and inner-AF40, disc degeneration may start within the NP. As
the degeneration becomes more severe, the cytoplasm and ECM in
the inner and outer-AF regions may become affected6,12,40.
Changes in GVA and location in degraded discs
We also found that the level of calpain generated GVA was
signiﬁcantly higher in grade V than in grade IV IVDs, suggesting not
only the presence of abundant amounts of GVA positive protein in
Fig. 2. Representative immunohistochemical analysis of the expression of m-calpain, m-calpain, and calpastatin in human IVD tissue at early and advanced stages of
degeneration. Samples from 12 patients (ﬁve early, four advanced, three LDH) were analyzed by immunohistochemistry, with the ﬁgure showing representative data from three
patients, at early (B) and advanced (C) stages of degeneration and LDH (D). The results in Fig. 2 are from the same patients as WB in Fig. 1B. (A) represents tissue samples incubated
with anti-rabbit-IgG. AF (inner-AF) and NP cells, including nuclei, from samples at early and advanced stages of degeneration samples were positive for each antibody. The nuclei,
cytoplasm and ECM in the samples at advanced stages of degeneration were also strongly positive (arrows). AF cells in samples at advanced stages of degeneration were more
strongly immunoreactive than samples from early stages of degeneration and LDH samples. Additionally, NP cells from samples at advanced stages of degeneration and LDH were
strongly immunoreactive to all antibodies. Bars: X100; 200 mm, X400; 50 mm.
S. Fukuta et al. / Osteoarthritis and Cartilage 19 (2011) 1254e1262 1259
Fig. 3. RepresentativeWestern blot analysis of the expression of GVA in human IVD
tissue at early and advanced stages of degeneration. Samples from the AF and NP
areas of human IVD tissue of 55 patients (ﬁve early, 45 advanced, ﬁve LDH) were
assayed by Western blotting with anti-GVA antibody. 20 mg GAG was loaded onto each
lane. The ﬁgure shows blotting of samples from six patients (one LDH, two early, three
advanced). The brackets (AeN) indicate that these pairs of AF and NP samples are from
the same patients. We observed a 140 kDa aggrecanase mediated aggrecan fragment
cleaved at the GVA domain in human IVD tissues during both early and advanced
stages of degeneration, with higher expression in advanced than in early stage.
Table IV
Percentage of immunopositive cells for calpains, calpastatin, and GVA in 3 different













m-calpain OAF 11  3.0 30  13 0.065 24  10 0.071
IAF 20  3.5 58  11 0.014 35  11 0.092
NP 17  3.2 72  10 0.014 73  7.3 0.025
m-calpain OAF 10  3.1 39  19 0.085 21  6.5 0.051
IAF 18  9.5 49  12 0.014 20  5.5 0.881
NP 13  3.3 63  16 0.014 52  10 0.025
Calpastatin OAF 6.4  2.4 22  10 0.081 11  3.8 0.070
IAF 12  3.3 43  10 0.014 12  2.5 0.882
NP 8.1  2.5 52  12 0.014 58  9.0 0.025
GVA OAF 8.2  2.7 20  9.2 0.108 30  18 0.051
IAF 19  4.1 63  13 0.014 54  14 0.025
NP 12  3.0 74  13 0.014 79  15 0.024
OAF: outer-AF, IAF: inner-AF. P value: vs early degenerated disc in each group.
ManneWhitney test.
S. Fukuta et al. / Osteoarthritis and Cartilage 19 (2011) 1254e12621260severely degraded IVDs but that m-calpain plays a long term dis-
aggregating function in human life. Additionally, the demonstra-
tion of both calpains and increased GVA in herniated disc samples
suggests that the calpains are involved not only in a gradual
degeneration process but also in the acute/subacute process of
inﬂammation. These ﬁndings may provide insight into the function
of calpains, not only in modulating cellular apoptosis and calciﬁ-
cation28,41, but also on the cleavage of aggrecan, which is involved
in maintaining the viscoelastic properties of IVD tissue.Balance of calpains and calpastatin
Alternations in the levels of expression of calpain and calpas-
tatin, along with differentiation have been reported in kidney and
brain tissue samples23,42,43. The balance between the calpains and
their endogenous inhibitor calpastatin is important in protecting
organs from pathological conditions44. We think the balance of
acceleration; calpain and blake: calpastatin is required to control
long term degeneration in IVD to prevent its special function. Many
studies have described howcalpastatin induces disease progression
or degeneration45,46. Our results suggest this balance in controlling
one aspect of degeneration in human IVD. Similarly, close correla-
tions have been observed between the activities of MMPs and the
levels of tissue inhibitor of metalloproteinase (TIMP) in normal
cartilage. Moreover, controlling inhibitors have been found to be
synthesized in parallel with degenerative enzymes in severely
degraded cartilage47,48 and IVD samples6,11. Thus, calpastatin may
be involved in preventing calpain activation prior to IVD degener-
ation. Knowledge of themechanism of inhibition of calpastatinmayTable III
Densitometric analysis of Western blotting for GVA protein in human IVD tissue
from early and advanced stages of degeneration and LDH. (M.D.; Mean Difference
shows difference between each groups (95%CI))contribute to the future development of therapeutic agents that
speciﬁcally inhibit the calpains, thus blocking degeneration of IVDs.Clinical relevance
The results described here may provide an explanation for the
mechanism by which calpain induces chemonucleolysis in rabbit
IVDs28. Following veriﬁcation of the safety and non-toxicity of
calpains, these enzymes can be used for chemonucleolysis,
although indications for this therapy are very limited. Further, our
ﬁndings suggest a future therapeutic approach toward IVD
degeneration by regulating the activity of the calpains. While
ADAMTS5, one of the aggrecanases, is involved in IVD degenera-
tion9,49 and injecting the anti-ADAMTS5 oligonucleotide in vivowas
found to restore degenerated IVDs49. Similarly, regulating calpain
function in the IVD might be effective in retarding IVD degenera-
tion. Future investigations of the interactions between calpains andFig. 4. Representative immunohistochemical analysis of GVA expression in human
IVD tissue at early and advanced stages of degeneration. Samples from 12 patients
(ﬁve early, four advanced, three LDH) were analyzed by immunohistochemistry, with
the ﬁgure showing representative data from three patients, at early (B) and advanced
(C) stages of degeneration and LDH (D). The results in Fig. 4 are from the same patients
as WB in Fig. 3. (A) represents tissue samples incubated with anti-rabbit-IgG. AF
(inner-AF) and NP cells, including nuclei, from early and advanced degenerated
samples, were positive for each antibody. Binding of anti-VPGVA was markedly posi-
tive in the nuclei and cytoplasm (arrows) and slightly positive in the ECM of both
inner-AF and NP areas. Bars: X100; 200 mm, X400; 50 mm.
S. Fukuta et al. / Osteoarthritis and Cartilage 19 (2011) 1254e1262 1261aggrecanase, as well as the relative potential of calpain in proteo-
lyzing aggrecans, are necessary.Limitation of the present study
This study had several limitations. We evaluated relative
expression of calpains, calpastatin and GVA by Western blotting.
Although several statistically signiﬁcant differences due to the
magnitude of IVD degeneration were observed, methodologically,
the assessment was semi-quantiﬁed. Future studies should utilize
more sophisticated methods enabling quantitative comparisons. In
addition, all evaluations in this study were of proteins. Further
analyses require assays of m-RNA levels. Second, the mechanisms
and pathways involved in regulating calpains and calpastatin were
not well analyzed. Further studies are needed to conﬁrm the
location of proteolysis induced by calpain, whether in the cyto-
plasm or ECM. It is also important to determine whether this type
of aggrecan processing achieves disc matrix organizational and
biochemical properties that promote or compromise tissue func-
tion. In the present study, the stages of early and advanced
degeneration were classiﬁed by Thompson grading using MRI.
Moreover, our early degeneration group included both children
with “early” degeneration and adults with “mild” degeneration.
Since aging promotes histological changes, alterations in ECM, and
increases in the numbers of apoptotic cells50, our “early” group
should be subdivided by patient age and analyzed separately in
a future study. Our understanding of disc degeneration would
therefore be signiﬁcantly enhanced if the expression of calpains
and aggrecan fragments cleaved by calpains is studied together
with IVD histology, alterations in matrix metabolism, and cell
apoptotic changes. Additionally, pairs of samples from the same
patients at early and advanced stages of IVD degeneration may
provide signiﬁcant information. Lastly, we recognize that this study
lacks a control group. To determine the potential involvement of
calpains in initiating degeneration, strict non-degenerate samples
should be studied as controls.Conclusion
Calpains, together with the degradation products of ECM
generated by m-calpainwere shown to be present in the NP and AF
of human IVD tissue, and could be quantitatively correlated with
the magnitude of disc degeneration. These results suggest that this
enzyme is involved in catabolic processes that occur during disc
degeneration. Calpains may be the focus of therapeutic approaches
to treat or at least slow down the degenerative cascade.Author contributions
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